Secukinumab

Drug Profile

Secukinumab

Alternative Names: AIN-457; Cosentyx; Human anti-interleukin-17A monoclonal antibody; KB-03303A; NVP-AIN 457; Scapho

Latest Information Update: 05 Jun 2017

Price : $50

At a glance

  • Originator Alcon; Novartis
  • Developer Icahn School of Medicine at Mount Sinai; Novartis
  • Class Anti-inflammatories; Antiasthmatics; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action IL17A protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Plaque psoriasis; Psoriatic arthritis
  • Registered Ankylosing spondylitis; Pustular psoriasis
  • Phase III Psoriasis; Rheumatoid arthritis
  • Phase II Alopecia areata; Atopic dermatitis
  • Discontinued Asthma; Crohn's disease; Dry eyes; Multiple sclerosis; Polymyalgia rheumatica; Type 1 diabetes mellitus; Uveitis

Most Recent Events

  • 23 May 2017 Rockefeller University and Novartis initiates a phase II trial for mild Plaque psoriasis in USA (NCT03131570)
  • 05 May 2017 Novartis plans the phase III SKIPPAIN trial for Spondylarthritis (NCT03136861)
  • 21 Mar 2017 Efficacy data from the phase III A2302E1 extension trial in Psoriasis released by Novartis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top